|
1
|
Lim MY, Raval JS, Richards KL, Zeidner JF, Foster MC. Lenalidomide-associated hemolytic anemia. Leuk Lymphoma 2015; 56:2717-9. [PMID: 25644743 DOI: 10.3109/10428194.2014.1003558] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Ming Y Lim
- a Division of Hematology/Oncology, Department of Medicine , University of North Carolina , Chapel Hill , NC , USA
| | - Jay S Raval
- b Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine , University of North Carolina , Chapel Hill , NC , USA
| | - Kristy L Richards
- a Division of Hematology/Oncology, Department of Medicine , University of North Carolina , Chapel Hill , NC , USA
| | - Joshua F Zeidner
- a Division of Hematology/Oncology, Department of Medicine , University of North Carolina , Chapel Hill , NC , USA
| | - Matthew C Foster
- a Division of Hematology/Oncology, Department of Medicine , University of North Carolina , Chapel Hill , NC , USA
| |
Collapse
|
|
2
|
Montefusco V. Underlying autoimmune diseases are not aggravated during treatment with lenalidomide in patients with mucosa-associated lymphoid tissue lymphoma: author's reply. Leuk Lymphoma 2015; 56:550. [DOI: 10.3109/10428194.2014.947979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
|
3
|
Montefusco V, Galli M, Spina F, Stefanoni P, Mussetti A, Perrone G, De Philippis C, Dalto S, Maura F, Bonini C, Rezzonico F, Pennisi M, Roncari L, Soldarini M, Dodero A, Farina L, Cocito F, Caprioli C, Corradini P. Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide. Leuk Lymphoma 2014; 55:2032-7. [DOI: 10.3109/10428194.2014.914203] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
|
4
|
Brauer DL, Edelman B, Rapoport AP, Hess JR, Akpek G. Plasma exchange and rituximab treatment for lenalidomide-associated cold agglutinin disease. Transfusion 2012; 52:2432-5. [DOI: 10.1111/j.1537-2995.2012.03608.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
|
5
|
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. Blood 2010; 116:180-2. [DOI: 10.1182/blood-2010-01-263087] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
Abstract
Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component. As lenalidomide has shown to be efficacious in both myelodysplastic syndromes and myeloproliferative neoplasms, we have treated 2 RARS-T patients, who were transfusion dependent, with lenalidomide. We report the results of lenalidomide treatment in these patients and show that lenalidomide has clinical activity in this rare disorder. Both patients became transfusion independent, and 1 of the patients attained indeed a complete molecular remission.
Collapse
|